Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promontory Completes Enrollment of PT112 in Castration-Resistant Prostate Cancer
Details : PT-112 (imifoplatin) is the first small-molecule conjugate of pyrophosphate in clinical development in oncology. It is being evaluated for metastatic castration-resistant prostate cancer.
Product Name : PT-112
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2024
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PT-112 is the first small-molecule conjugate of pyrophosphate in clinical development in oncology and inhibitor of ribosomal biogenesis (RiBi) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironm...
Product Name : PT-112
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2023
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PT-112 (imifoplatin) is the first small-molecule conjugate of pyrophosphate in clinical development in oncology and inhibitor of ribosomal biogenesis (RiBi) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor...
Product Name : PT-112
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2023
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PT-112 is the first small-molecule conjugate of pyrophosphate that promotes immunogenic cell death, through the release of damage associated molecular patterns that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tu...
Product Name : PT-112
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PT-112 is the first small-molecule conjugate of pyrophosphate, and possesses a unique pleiotropic MOA that promotes ICD, through the release of DAMPs that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microe...
Product Name : PT-112
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imifoplatin,Avelumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs).
Product Name : PT-112
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Imifoplatin,Avelumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PT-112 is the first small-molecule conjugate of pyrophosphate in oncology, and possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD) through the release of damage associated molecular patterns (DAMPs) that bind to ...
Product Name : PT-112
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Imifoplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable